2. Kaspers GJ, Creutzig U. 2005; Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 19:2025–9. DOI:
10.1038/sj.leu.2403958. PMID:
16304569.
Article
3. Gibson BE, Wheatley K, Hann IM, et al. 2005; Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 19:2130–8. DOI:
10.1038/sj.leu.2403924. PMID:
16304572.
Article
4. Rasche M, Zimmermann M, Borschel L, et al. 2018; Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 32:2167–77. DOI:
10.1038/s41375-018-0071-7. PMID:
29550834. PMCID:
PMC6170392.
Article
5. Rubnitz JE, Inaba H, Dahl G, et al. 2010; Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 11:543–52. DOI:
10.1016/S1470-2045(10)70090-5.
Article
7. Arber DA, Orazi A, Hasserjian R, et al. 2016; The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–405. DOI:
10.1182/blood-2016-03-643544. PMID:
27069254.
Article
8. Davila J, Slotkin E, Renaud T. 2014; Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments. Paediatr Drugs. 16:151–68. DOI:
10.1007/s40272-013-0048-y. PMID:
24158739.
Article
9. Gamis AS, Alonzo TA, Meshinchi S, et al. 2014; Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol. 32:3021–32. DOI:
10.1200/JCO.2014.55.3628. PMID:
25092781. PMCID:
PMC4162498.
Article
10. Nagarajan R, Gerbing R, Alonzo T, et al. 2019; Quality of life in pediatric acute myeloid leukemia: report from the Children's Oncology Group. Cancer Med. 8:4454–64. DOI:
10.1002/cam4.2337. PMID:
31190442. PMCID:
PMC6675729.
Article
11. Hann IM, Stevens RF, Goldstone AH, et al. 1997; Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 89:2311–8. DOI:
10.1182/blood.V89.7.2311. PMID:
9116274.
12. Burnett AK, Russell NH, Hills RK, et al. 2013; Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 31:3360–8. DOI:
10.1200/JCO.2012.47.4874. PMID:
23940227.
Article
13. Creutzig U, Ritter J, Zimmermann M, et al. 2001; Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 19:2705–13. DOI:
10.1200/JCO.2001.19.10.2705. PMID:
11352963.
14. Creutzig U, Ritter J, Zimmermann M, et al. 2001; Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 15:348–54. DOI:
10.1038/sj.leu.2402046. PMID:
11237056.
15. Gibson BE, Webb DK, Howman AJ, et al. 2011; Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 155:366–76. DOI:
10.1111/j.1365-2141.2011.08851.x. PMID:
21902686.
Article
16. Creutzig U, Zimmermann M, Bourquin JP, et al. 2013; Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 122:37–43. DOI:
10.1182/blood-2013-02-484097. PMID:
23704089.
Article
17. Getz KD, Alonzo TA, Sung L, et al. 2017; Four versus five chemotherapy courses in patients with low risk acute myeloid leukemia: a Children's Oncology Group report. J Clin Oncol. 35(Suppl 15):10515. DOI:
10.1200/JCO.2017.35.15_suppl.10515.
Article
18. Aplenc R, Alonzo TA, Gerbing RB, et al. 2008; Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol. 26:2390–3295. DOI:
10.1200/JCO.2007.13.0096. PMID:
18467731. PMCID:
PMC4558626.
Article
19. Jen EY, Ko CW, Lee JE, et al. 2018; FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 24:3242–6. DOI:
10.1158/1078-0432.CCR-17-3179. PMID:
29476018.
Article
20. Cooper TM, Franklin J, Gerbing RB, et al. 2012; AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 118:761–9. DOI:
10.1002/cncr.26190. PMID:
21766293.
21. Woods WG, Neudorf S, Gold S, et al. 2001; A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 97:56–62. DOI:
10.1182/blood.V97.1.56. PMID:
11133742.
22. Ravindranath Y, Yeager AM, Chang MN, et al. 1996; Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med. 334:1428–34. DOI:
10.1056/NEJM199605303342203. PMID:
8618581.
23. Horan JT, Alonzo TA, Lyman GH, et al. 2008; Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol. 26:5797–801. DOI:
10.1200/JCO.2007.13.5244. PMID:
18955460. PMCID:
PMC2645105.
Article
24. Tsukimoto I, Tawa A, Horibe K, et al. 2009; Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 27:4007–13. DOI:
10.1200/JCO.2008.18.7948. PMID:
19620491.
Article
25. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. 2010; A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 116:2205–14. DOI:
10.1182/blood-2010-01-261800. PMID:
20538803.
Article
26. Bitan M, He W, Zhang MJ, et al. 2014; Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 123:1615–20. DOI:
10.1182/blood-2013-10-535716. PMID:
24435046. PMCID:
PMC3945869.
Article
27. Harris AC, Boelens JJ, Ahn KW, et al. 2016; Comparison of outcomes for myeloablative conditioning regimens combining busulfan with either cyclophosphamide or fludarabine in children. Blood (ASH Annual Meeting Abstracts). 128(Suppl 22):664. DOI:
10.1182/blood.V128.22.664.664.
Article
28. Weisser M, Kern W, Rauhut S, et al. 2005; Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia. 19:1416–23. DOI:
10.1038/sj.leu.2403809. PMID:
15920493.
Article
29. Loken MR, Alonzo TA, Pardo L, et al. 2012; Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 120:1581–8. DOI:
10.1182/blood-2012-02-408336. PMID:
22649108. PMCID:
PMC3429302.
Article
30. Viehmann S, Teigler-Schlegel A, Bruch J, Langebrake C, Reinhardt D, Harbott J. 2003; Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia. 17:1130–6. DOI:
10.1038/sj.leu.2402959. PMID:
12764380.
Article
31. Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. 2012; Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 120:2826–35. DOI:
10.1182/blood-2012-06-435669. PMID:
22875911.
Article
32. Gaballa S, Saliba R, Oran B, et al. 2017; Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 92:331–7. DOI:
10.1002/ajh.24632. PMID:
28052408. PMCID:
PMC5352512.
Article
33. Ivey A, Hills RK, Simpson MA, et al. 2016; Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 374:422–33. DOI:
10.1056/NEJMoa1507471. PMID:
26789727.
Article
34. Zhao X, Wang Z, Ruan G, et al. 2018; Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Ann Hematol. 97:967–75. DOI:
10.1007/s00277-018-3265-1. PMID:
29423758.
Article
36. von Neuhoff C, Reinhardt D, Sander A, et al. 2010; Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 28:2682–9. DOI:
10.1200/JCO.2009.25.6321. PMID:
20439630.
Article
37. Kutny MA, Alonzo TA, Gerbing RB, et al. 2017; Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the Children's Oncology Group phase III historically controlled trial AAML0631. J Clin Oncol. 35:3021–9. DOI:
10.1200/JCO.2016.71.6183. PMID:
28767288. PMCID:
PMC5590801.
Article
38. Cortes J, Kantarjian HM, Kadia TM, et al. 2019; Value of minimal residual disease (MRD) monitoring using real-time quantitative PCR in patients with acute promyelocytic leukemia (APL) treated with ATRA, ATO, +/- GO. Blood (ASH Annual Meeting Abstracts). 134(Suppl):3851. DOI:
10.1182/blood-2019-124599.
Article
39. Fenaux P, Chastang C, Chevret S, et al. 1999; A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 94:1192–200. DOI:
10.1182/blood.V94.4.1192. PMID:
10438706.
40. Powell BL, Moser B, Stock W, et al. 2010; Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 116:3751–7. DOI:
10.1182/blood-2010-02-269621. PMID:
20705755. PMCID:
PMC2981533.
Article
41. Gamis AS, Alonzo TA, Gerbing RB, et al. 2011; Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood. 118:6752–9. quiz 996DOI:
10.1182/blood-2011-04-350017. PMID:
21849481. PMCID:
PMC3245202.
Article
42. Ravindranath Y, Abella E, Krischer JP, et al. 1992; Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 80:2210–4. DOI:
10.1182/blood.V80.9.2210.2210. PMID:
1384797.
43. Sorrell AD, Alonzo TA, Hilden JM, et al. 2012; Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer. 118:4806–14. DOI:
10.1002/cncr.27484. PMID:
22392565. PMCID:
PMC3879144.
45. Hitzler JK, Berman J, Gerbing RB, et al. 2019; High-dose cytarabine is indispensable for the survival of children with myeloid leukemia of down syndrome despite negative minimal residual disease post-induction. Blood (ASH Annual Meeting Abstracts). 134(Suppl):118. DOI:
10.1182/blood-2019-126723.
Article
47. Schlenk RF, Kayser S, Bullinger L, et al. 2014; Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 124:3441–9. DOI:
10.1182/blood-2014-05-578070. PMID:
25270908.
Article
48. Tarlock K, Alonzo TA, Gerbing RB, et al. 2016; Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. Clin Cancer Res. 22:1951–7. DOI:
10.1158/1078-0432.CCR-15-1349. PMID:
26644412. PMCID:
PMC4834220.
Article
49. Perl AE, Martinelli G, Cortes JE, et al. 2019; Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 381:1728–40. DOI:
10.1056/NEJMoa1902688. PMID:
31665578.
50. Stone RM, Mandrekar SJ, Sanford BL, et al. 2017; Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 377:454–64. DOI:
10.1056/NEJMoa1614359. PMID:
28644114. PMCID:
PMC5754190.
52. Sander A, Zimmermann M, Dworzak M, et al. 2010; Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia. 24:1422–8. DOI:
10.1038/leu.2010.127. PMID:
20535146.
Article
53. Burnett AK, Hills RK, Milligan DW, et al. 2010; Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 28:586–95. DOI:
10.1200/JCO.2009.22.9088. PMID:
20038732.
Article
54. Nakayama H, Tabuchi K, Tawa A, et al. 2014; Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol. Int J Hematol. 100:171–9. DOI:
10.1007/s12185-014-1616-9. PMID:
24961644.
Article
55. Kaspers GJ, Zimmermann M, Reinhardt D, et al. 2013; Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 31:599–607. DOI:
10.1200/JCO.2012.43.7384. PMID:
23319696.
Article
56. Shukla N, Kobos R, Renaud T, Steinherz LJ, Steinherz PG. 2014; Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. Pediatr Blood Cancer. 61:431–5. DOI:
10.1002/pbc.24789. PMID:
24115731.
Article
57. Cooper TM, Alonzo TA, Gerbing RB, et al. 2014; AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 120:2482–9. DOI:
10.1002/cncr.28674. PMID:
24771494. PMCID:
PMC4126862.
Article
58. Miano M, Pistorio A, Putti MC, et al. 2012; Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma. 53:1693–8. DOI:
10.3109/10428194.2012.663915. PMID:
22303898.
Article
59. Niktoreh N, Lerius B, Zimmermann M, et al. 2019; Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. Haematologica. 104:120–7. DOI:
10.3324/haematol.2018.191841. PMID:
30093401. PMCID:
PMC6312035.
Article
60. Cooper TM, Absalon M, Alonzo TA, et al. 2019; AAML 1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): a report from the Children's Oncology Group. J Clin Oncol. 37(Suppl 15):10003. DOI:
10.1200/JCO.2019.37.15_suppl.10003.
Article
61. van Eijkelenburg NKA, Rasche M, Ghazaly E, et al. 2018; Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. Haematologica. 103:1484–92. DOI:
10.3324/haematol.2017.187153. PMID:
29773602. PMCID:
PMC6119144.
Article
62. Messinger Y, Boklan J, Goldberg J, et al. 2017; Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia. Pediatr Hematol Oncol. 34:187–98. DOI:
10.1080/08880018.2017.1360970. PMID:
29039989.
Article
63. Cooper TM, Sison EAR, Baker SD, et al. 2017; A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). Pediatr Blood Cancer. 64:e26414. DOI:
10.1002/pbc.26414. PMID:
28409853. PMCID:
PMC5675008.
64. Horton TM, Perentesis JP, Gamis AS, et al. 2014; A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 61:1754–60. DOI:
10.1002/pbc.25117. PMID:
24976003. PMCID:
PMC4247259.
Article
65. Inaba H, Rubnitz JE, Coustan-Smith E, et al. 2011; Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol. 29:3293–300. DOI:
10.1200/JCO.2011.34.7427. PMID:
21768474. PMCID:
PMC3158600.
Article
66. Inaba H, Stewart CF, Crews KR, et al. 2010; Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer. 116:98–105. DOI:
10.1002/cncr.24712. PMID:
19885837. PMCID:
PMC2920745.
Article
68. Hijiya N, Gaynon P, Barry E, et al. 2009; A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 23:2259–64. DOI:
10.1038/leu.2009.185. PMID:
19741725.
Article
69. Jeha S, Razzouk B, Rytting M, et al. 2009; Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 27:4392–7. DOI:
10.1200/JCO.2008.18.8706. PMID:
19652076. PMCID:
PMC2744276.
Article
70. Krauss AC, Gao X, Li L, et al. 2019; FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. Clin Cancer Res. 25:2685–90. DOI:
10.1158/1078-0432.CCR-18-2990. PMID:
30541745.
Article
71. Taylor SM, Jones PA. 1979; Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell. 17:771–9. DOI:
10.1016/0092-8674(79)90317-9. PMID:
90553.
73. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. 2010; Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 28:562–9. DOI:
10.1200/JCO.2009.23.8329. PMID:
20026804.
Article